Evozyne, founded in 2019, is an artificial intelligence and biotechnology company that uses generative AI models with the goal of creating advanced therapeutic proteins and pharmaceuticals. The company’s platform was built on an AI model called ProT-VAE that was trained by AI hardware company Nvidia, and it is designed to read sequences on amino acids with the goal of enabling it to understand how nature assembles proteins. Evozyne is headquartered in Chicago, Illinois.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/27/2023 | Series B | $50MM | $xx.xx | $288.32MM | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | |
Price per Share
$xx.xx
Shares Outstanding
3,228,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners
|
||||||
04/09/2021 | Series A | $59.18MM | $xx.xx | $295.92MM | Paragon Biosciences, Valor Equity Partners | |
Price per Share
$xx.xx
Shares Outstanding
2,633,899
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Paragon Biosciences, Valor Equity Partners
|